CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 65 enrolled
Drug / intervention
Biological: Experimental: Tezepelumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04048343
NCT04048343Phase 3Completed
CompareCT.gov

A 52-Week, Open-Label, Multicentre Study to Evaluate the Safety of Tezepelumab in Japanese Adults and Adolescents With Inadequately Controlled Severe Asthma (NOZOMI)

AstraZeneca·interventional·Posted Aug 7, 2019·Updated Jun 1, 2022

In Brief

A Phase 3 clinical trial evaluating Biological: Experimental: Tezepelumab for Severe Asthma. Completed, enrolled 65 participants across 5 sites.

Detailed Summary

This is an open-label, single arm study designed to evaluate the safety of tezepelumab administered subcutaneously every 4 weeks in Japanese adult and adolescent subjects with inadequately controlled severe asthma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSevere Asthma
CountriesJapan
CollaboratorsAmgen

Timeline

Phase 3CompletedFinished
2020202120222023202420252026
First PostedAug 7, 2019
Enrollment StartJun 10, 2019
Primary CompletionMar 18, 2021
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 6.9 years ago

Interventions

Biological: Experimental: Tezepelumabdrug

Tezepelumab subcutaneous injection every 4 weeks